glp-1 agonists in development Market Overview: and the Obesity Market | Blog GLP-1 receptor agonists | How
Description
Triple agonists (GLP-1/GIP/glucagon) further extend these effects by enhancing energy expenditure and reducing hepatic fat and inflammation
Given the enormity of the challenge of obesity and the lack of adequate treatment options, it seems unfair to consider weight as an indicator of personal value
Published clinical trial data suggests retatrutide produces more pronounced metabolic effects than earlier-generation compounds in the populations studied
doi: 10.1210/en.2003-0007
